Evidence map›Paper›PMID 32489086›Full record

ArticleJBRA assisted reproduction2020

Evaluation of the safety and efficacy of corifollitropin alfa combined with GnRH agonist triggering in oocyte donation cycles. A prospective longitudinal study.

Ioannis Tsakiridis, Robert Najdecki, Petroula Tatsi, Evi Timotheou, Kallirhoe Kalinderi, Georgios Michos, Andriana Virgiliou, Hakan Yarali, Apostolos Athanasiadis, Evangelos G Papanikolaou

Registry-linked trialOpen access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JBRA assisted reproduction, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06134479 (Comparison of Sequential CFA vs CFA +rFSH for Elective Fertility Preservation.. The 2-shot Protocol.), which is not on this map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06134479 phase3completednot on this mapstarted 2023, after this paper: background citation

Comparison of Sequential CFA vs CFA +rFSH for Elective Fertility Preservation.. The 2-shot Protocol.

TypeinterventionalSponsorFundación Santiago Dexeus FontRan2023 to 2025Enrolled194ConditionsFertilityArms150μg CFA (Elonva®) at stimulation day (SD) 1 and 100μg CFA(Elonva®) at SD 5, 150μg CFA (Elonva®) at SD 1 following by rFSH (Puregon®) 200IU daily from SD 8 until the day of the trigger
3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Pregnancy Outcomes FollowingIn vivo (Athens, Greece)
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Ioannis Tsakiridis3rd Department Ob-Gyn, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Robert NajdeckiAssisting Nature, Center of Reproduction & Genetics, Thessaloniki, Greece.
Petroula TatsiAssisting Nature, Center of Reproduction & Genetics, Thessaloniki, Greece.
Evi TimotheouAssisting Nature, Center of Reproduction & Genetics, Thessaloniki, Greece.
Kallirhoe Kalinderi3rd Department Ob-Gyn, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Georgios Michos3rd Department Ob-Gyn, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Andriana Virgiliou3rd Department Ob-Gyn, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Hakan YaraliHacetepe University, Ankara, Turkey.
Apostolos Athanasiadis3rd Department Ob-Gyn, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Evangelos G Papanikolaou3rd Department Ob-Gyn, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Aristotle University of Thessaloniki · GRAssisting Nature · GRHacettepe University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveIn order to help make the dream of parenthood come true for oocyte acceptors, it is essential that the procedure is not dangerous or unpleasant for oocyte donors. The aim of this study was to identify differences in safety, efficacy and patient acceptability between a traditional stimulation antagonist protocol with recombinant-FSH (rFSH) with hCG-triggering, compared with an innovative antagonist protocol with corifollitropin alfa (Elonva®) plus GnRH agonist triggering in oocyte donors.

methodsA prospective longitudinal study was conducted at an in vitro fertilization center in Greece. The same eighty donors underwent two consecutive antagonist stimulation schemes. Primary outcomes were patient satisfaction (scored by a questionnaire) and delivery rate per donor. Secondary outcomes were mean number of cumulus-oocyte-complexes, metaphase II (MII) oocytes and ovarian hyperstimulation syndrome (OHSS) rate.

resultsDonors reported better adherence and less discomfort with the corifollitropin alpha + GnRH agonist-triggering protocol (p<0.001). No significant differences were identified in the clinical pregnancy rate per donor (p=0.13), the delivery rates, the number of oocytes (p=0.35), the number of MII oocytes (p=0.50) and the number of transferred embryos, between the two protocols. However, the luteal phase duration was significantly shorter (p<0.001) in the corifollitropin alpha + GnRH agonist-triggering protocol. Moreover, three cases of moderate OHSS (3.75%) were identified after hCG triggering, whereas no case of OHSS occurred after GnRH agonist ovulation induction (p=0.25).

conclusionThe use of corifollitropin alpha combined with a GnRH agonist for triggering is a safe, effective and acceptable protocol for oocyte donors.

Indexed as

AdultFemaleFertility Agents, FemaleFollicle Stimulating Hormone, HumanGonadotropin-Releasing HormoneHumansLongitudinal StudiesOocyte DonationOocytesOvulation InductionPregnancyPregnancy RateProspective StudiesYoung AdultFertility Agents, FemaleFollicle Stimulating Hormone, Humanfollicle stimulating hormone, human, with HCG C-terminal peptideGonadotropin-Releasing Hormonecorifollitropin alfadonorGnRH agonist triggeringIVFoocyte donation

Identifiers

PMID32489086
PMCPMC7558885
OpenAlexW3024301266

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.